Interfyl® Connective Tissue Matrix (CTM)
Interfyl® is a decellularized human placental CTM to be used for the replacement or supplementation of damaged or inadequate integumental tissue. Unlike standard therapies, Interfyl CTM provides a native extracellular matrix for cell attachment, as shown in in vitro data.!
What Makes Interfyl Connective Tissue Unique?
- Does Not Contain Amnion: Interfyl connective tissue contains only CTM.
- The Chorion Difference: The only CTM filler derived exclusively from the chorionic plate of the human placenta.
- Minimally Processed: Minimal processing helps retain the fundamental structure and functional characteristics of native connective tissue.
Interfyl® CTM provided a natural, native extracellular matrix (ECM) that supported efficient transition from M1 macrophages (pro-inflammatory) to M2 macrophages (which support healing and remodeling).
Pro-inflammatory Factors
Demonstrated a steady decrease of pro-inflammatory factors over six days.
Anti-inflammatory Factors
Demonstrated a steady increase of anti-inflammatory factors over six days.
Development of Tubular Branches
Interfyl CTM supports tube formation by endothelial cells, a precursor to angiogenesis, which enables blood flow and revascularization of the damaged tissue.
